Cell Biotech-Biomi Collaborate on Microbiome Therapeutics Development

Cell Biotech announced on the 30th that it has signed a Memorandum of Understanding (MOU) with Biomi for the development and commercialization of microbiome-based microbial therapeutics.

On the 29th, at Yonsei University Sinchon Campus in Seodaemun-gu, Seoul, Yoon Sang-sun, CEO of Biomi (left), and Kim Kwang-yong, director of Cell Biotech, are posing for a commemorative photo at the signing ceremony of the business agreement between Cell Biotech and Biomi.
[Photo by Cell Biotech]

The MOU signing ceremony held the day before at Yonsei University Sinchon Campus in Seodaemun-gu, Seoul, was attended by Myungjun Jeong, CEO of Cell Biotech, Kwangyong Kim, Director of Cell Biotech, and Sangseon Yoon, CEO of Biomi. Through this agreement, both companies agreed to promote various forms of cooperation for microbiome drug development, including ▲manufacturing and quality control testing of clinical trial drugs ▲sharing of microbial therapeutic materials ▲sharing experiences for Investigational New Drug (IND) approval.

Biomi possesses five new drug development pipelines, including the antibiotic-resistant bacterial infection treatment ‘BM111’ and cardiovascular disease treatment ‘BM109,’ based on its complex strain technology. Cell Biotech is developing a colorectal cancer treatment ‘PP-P8’ based on its technology that has researched various functionalities of Korean-origin lactic acid bacteria.

Cell Biotech has shown an active approach to new drug development by investing about 10% of its annual sales in research and development (R&D) costs. The company plans to secure mass production technology for strains and directly supply new drugs needed for clinical trials by constructing a biological formulation pharmaceutical factory, aiming to preempt the domestic microbiome-related pharmaceutical strain contract development and manufacturing organization (CDMO) business.

Myungjun Jeong, CEO of Cell Biotech, said, “Although the U.S. Food and Drug Administration (FDA) recently approved the first microbiome therapeutic, attracting attention from the bio industry, the development gap between domestic and overseas companies is not yet large, and the elucidation of the mechanism of action and commercialization of therapeutics are still in the early stages. We hope you pay attention to the achievements that Cell Biotech and Biomi will accomplish as the best partners.” Sangseon Yoon, CEO of Biomi, said, “We are very pleased to collaborate with Cell Biotech, which has secured world-class microbiome technology and brand competitiveness. The synergy between Biomi’s new drug development pipelines and Cell Biotech’s 28 years of research know-how will establish us as a leading representative of the microbiome industry in Korea.”

This content was produced with the assistance of AI translation services.